Compare Stocks: RXRX, CGON, COGT, and SRRK

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CGON CG Oncology	$77.11 +2.8%	$69.60	$24.85 ▼ $79.39	$6.65B	0.23	805,454 shs	958,312 shs
COGT Cogent Biosciences	$37.87 -0.2%	$38.14	$11.53 ▼ $43.73	$6.58B	0.38	1.86 million shs	1.59 million shs
RXRX Recursion Pharmaceuticals	$3.11 -1.6%	$3.28	$2.77 ▼ $7.18	$1.69B	1.03	15.53 million shs	10.59 million shs
SRRK Scholar Rock	$52.05 -0.9%	$50.97	$27.07 ▼ $58.49	$6.40B	0.69	1.03 million shs	778,684 shs

The 7 Hottest IPO Stories of 2026

MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CGON CG Oncology	+2.77%	+0.72%	+7.32%	+21.82%	+200.04%
COGT Cogent Biosciences	-0.16%	-8.81%	-3.10%	+21.18%	+218.50%
RXRX Recursion Pharmaceuticals	-1.58%	-5.47%	+5.78%	+9.12%	-46.10%
SRRK Scholar Rock	-0.89%	+0.31%	-1.53%	+9.44%	+65.71%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CGON CG Oncology	$77.11 +2.8%	$69.60	$24.85 ▼ $79.39	$6.65B	0.23	805,454 shs	958,312 shs
COGT Cogent Biosciences	$37.87 -0.2%	$38.14	$11.53 ▼ $43.73	$6.58B	0.38	1.86 million shs	1.59 million shs
RXRX Recursion Pharmaceuticals	$3.11 -1.6%	$3.28	$2.77 ▼ $7.18	$1.69B	1.03	15.53 million shs	10.59 million shs
SRRK Scholar Rock	$52.05 -0.9%	$50.97	$27.07 ▼ $58.49	$6.40B	0.69	1.03 million shs	778,684 shs

The 7 Hottest IPO Stories of 2026

MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CGON CG Oncology	+2.77%	+0.72%	+7.32%	+21.82%	+200.04%
COGT Cogent Biosciences	-0.16%	-8.81%	-3.10%	+21.18%	+218.50%
RXRX Recursion Pharmaceuticals	-1.58%	-5.47%	+5.78%	+9.12%	-46.10%
SRRK Scholar Rock	-0.89%	+0.31%	-1.53%	+9.44%	+65.71%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CGON CG Oncology	2.71	Moderate Buy	$83.18	7.87% Upside
COGT Cogent Biosciences	2.85	Moderate Buy	$49.40	30.45% Upside
RXRX Recursion Pharmaceuticals	2.20	Hold	$8.06	159.16% Upside
SRRK Scholar Rock	3.12	Buy	$57.71	10.88% Upside

Current Analyst Ratings Breakdown

Latest RXRX, CGON, COGT, and SRRK Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/17/2026	RXRX Recursion Pharmaceuticals	Morgan Stanley Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$5.30
8/17/2026	COGT Cogent Biosciences	Piper Sandler Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$52.00 ➝ $55.00
8/13/2026	SRRK Scholar Rock	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$56.00 ➝ $63.00
8/12/2026	COGT Cogent Biosciences	Guggenheim Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$45.00 ➝ $52.00
8/10/2026	SRRK Scholar Rock	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$65.00
8/10/2026	SRRK Scholar Rock	Wedbush Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Outperform	$58.00
8/7/2026	SRRK Scholar Rock	BMO Capital Markets Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Outperform	$76.00
8/7/2026	SRRK Scholar Rock	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$58.00 ➝ $60.00
8/7/2026	CGON CG Oncology	Royal Bank Of Canada Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Outperform	$81.00 ➝ $79.00
8/7/2026	CGON CG Oncology	Piper Sandler Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$82.00 ➝ $85.00
8/7/2026	CGON CG Oncology	Truist Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$82.00 ➝ $85.00

(Data available from 8/18/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CGON CG Oncology	$4.04M	1,691.84	N/A	N/A	$9.33 per share	8.26
COGT Cogent Biosciences	N/A	N/A	N/A	N/A	$3.84 per share	N/A
RXRX Recursion Pharmaceuticals	$74.68M	22.29	N/A	N/A	$2.14 per share	1.45
SRRK Scholar Rock	N/A	N/A	N/A	N/A	$2.41 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CGON CG Oncology	-$160.99M	-$2.69	N/A	N/A	N/A	-3,602.68%	-25.20%	-23.98%	N/A
COGT Cogent Biosciences	-$328.94M	-$2.16	N/A	N/A	N/A	N/A	-84.47%	-47.72%	11/6/2026 (Estimated)
RXRX Recursion Pharmaceuticals	-$644.76M	-$1.04	N/A	N/A	N/A	-945.94%	-50.41%	-38.25%	11/4/2026 (Estimated)
SRRK Scholar Rock	-$377.94M	-$3.45	N/A	N/A	N/A	N/A	-160.19%	-87.18%	N/A

Latest RXRX, CGON, COGT, and SRRK Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/10/2026	Q2 2026	COGT Cogent Biosciences	-$0.5550	-$0.52	+$0.0350	-$0.52	$0.00 million	N/A
8/6/2026	Q2 2026	CGON CG Oncology	-$0.6642	-$0.90	-$0.2359	-$0.90	$0.36 million	$1.16 million
8/6/2026	Q2 2026	SRRK Scholar Rock	-$0.8405	-$0.84	+$0.0005	-$0.84	$3.33 million	N/A
8/5/2026	Q2 2026	RXRX Recursion Pharmaceuticals	-$0.24	-$0.25	-$0.01	-$0.25	$10.97 million	$7.67 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
CGON CG Oncology	N/A	N/A	N/A	N/A	N/A
COGT Cogent Biosciences	N/A	N/A	N/A	N/A	N/A
RXRX Recursion Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
SRRK Scholar Rock	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CGON CG Oncology	N/A	22.22	22.20
COGT Cogent Biosciences	0.48	13.57	13.57
RXRX Recursion Pharmaceuticals	0.01	5.03	5.03
SRRK Scholar Rock	0.77	7.02	7.02

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CGON CG Oncology	26.56%
COGT Cogent Biosciences	N/A
RXRX Recursion Pharmaceuticals	89.06%
SRRK Scholar Rock	91.08%

Insider Ownership

Company	Insider Ownership
CGON CG Oncology	4.80%
COGT Cogent Biosciences	6.59%
RXRX Recursion Pharmaceuticals	6.65%
SRRK Scholar Rock	10.30%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CGON CG Oncology	61	88.64 million	84.39 million	Optionable
COGT Cogent Biosciences	80	173.53 million	162.09 million	Optionable
RXRX Recursion Pharmaceuticals	400	535.34 million	499.74 million	Optionable
SRRK Scholar Rock	140	121.79 million	109.24 million	Optionable

RXRX, CGON, COGT, and SRRK Headlines

Recent News About These Companies

Scholar Rock Eyes Sept. 30 FDA Decision for SMA Drug Apitegromab

August 17 at 7:02 PM | marketbeat.com

Canaccord Genuity Keeps Their Buy Rating on Scholar Rock Holding (SRRK)

August 16 at 2:10 PM | theglobeandmail.com

Is Scholar Rock Holding Corporation (SRRK) Better Positioned than Novo Nordisk A/S (NVO) After Recent Setbacks?

August 16 at 4:10 AM | finance.yahoo.com

Is Scholar Rock Holding Corporation (SRRK) Better Positioned than Novo Nordisk A/S (NVO) After Recent Setbacks?

August 14, 2026 | insidermonkey.com

Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

August 14, 2026 | businesswire.com

Scholar Rock (NASDAQ:SRRK) Stock Price Expected to Rise, JPMorgan Chase & Co. Analyst Says

August 13, 2026 | marketbeat.com

Scholar Rock (SRRK) Q2 2026 Earnings Call Transcript

August 13, 2026 | finance.yahoo.com

Q3 EPS Estimates for Scholar Rock Decreased by HC Wainwright

August 13, 2026 | americanbankingnews.com

Scholar Rock (NASDAQ:SRRK) Earns "Outperform" Rating from Wedbush

August 12, 2026 | americanbankingnews.com

Q3 EPS Estimates for Scholar Rock Cut by HC Wainwright

August 11, 2026 | marketbeat.com

Bank of America Corp DE Buys 286,126 Shares of Scholar Rock Holding Corporation $SRRK

August 11, 2026 | marketbeat.com

Scholar Rock's (SRRK) Outperform Rating Reiterated at Wedbush

August 10, 2026 | marketbeat.com

Scholar Rock Announces FDA Review of Apitegromab Biologics License Application (BLA) for Spinal Muscular Atrophy (SMA) to Progress with Second Fill-Finish Facility; Approval ...

August 8, 2026 | uk.finance.yahoo.com

Scholar Rock drops Catalent facility from marketing application for muscle weakness drug

August 7, 2026 | reuters.com

Scholar Rock Announces FDA Review of Apitegromab Biologics License Application (BLA) for Spinal Muscular Atrophy (SMA) to Progress with Second Fill-Finish Facility; Approval Decision Anticipated by September 30, 2026 Action Date

August 7, 2026 | businesswire.com

Scholar Rock Q2 Earnings Call Highlights

August 7, 2026 | marketbeat.com

Scholar Rock (NASDAQ:SRRK) Releases Earnings Results, Meets Estimates

August 6, 2026 | marketbeat.com

Scholar Rock Reports Second Quarter 2026 Financial Results and Recent Business Highlights

August 6, 2026 | finance.yahoo.com

Scholar Rock Holding Corporation (SRRK) Q2 2026 Earnings Call Transcript

August 6, 2026 | seekingalpha.com

Sei Investments Co. Grows Position in Scholar Rock Holding Corporation $SRRK

August 4, 2026 | marketbeat.com

Scholar Rock Holding Corporation $SRRK Shares Bought by Janus Henderson Group PLC

August 1, 2026 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

RXRX, CGON, COGT, and SRRK Company Descriptions

CG Oncology NASDAQ:CGON

$77.11 +2.08 (+2.77%)

Closing price 08/17/2026 04:00 PM Eastern

Extended Trading

$76.68 -0.43 (-0.55%)

As of 05:14 AM Eastern

CG Oncology, Inc., an oncolytic immunotherapy company, focuses on developing and commercializing backbone bladder-sparing therapeutics for patients with bladder cancer. The company develops BOND-003 for the treatment of high-risk bacillus calmette guerin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) patients; CORE-001 to treat cretostimogene in combination with pembrolizumab in high-risk BCG-unresponsive NMIBC patients; and CORE-002 for the treatment of cretostimogene in combination with the checkpoint inhibitor nivolumab in muscle invasive bladder cancer patients. It also develops PIVOT-006, a cretostimogene monotherapy for intermediate-risk NMIBC following transurethral resection of the bladder tumor; and CORE-008 for treating patients with high-risk NMIBC, including BCG-exposed and BCG-naïve NMIBC patients. CG Oncology, Inc. was formerly known as Cold Genesys, Inc. and changed its name to CG Oncology, Inc. in June 2020. The company was founded in 2010 and is based in Irvine, California.

Cogent Biosciences NASDAQ:COGT

$37.87 -0.06 (-0.16%)

Closing price 08/17/2026 04:00 PM Eastern

Extended Trading

$37.65 -0.22 (-0.58%)

As of 04:59 AM Eastern

Cogent Biosciences, Inc., a biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes bezuclastinib (CGT9486), a selective tyrosine kinase inhibitor designed to target mutations within the KIT receptor tyrosine kinase, including KIT D816V KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors. The company has a licensing agreement with Plexxikon Inc. for the research, development, and commercialization of bezuclastinib. The company was formerly known as Unum Therapeutics Inc. and changed its name to Cogent Biosciences, Inc. in October 2020. Cogent Biosciences, Inc. was incorporated in 2014 and is headquartered in Waltham, Massachusetts.

Recursion Pharmaceuticals NASDAQ:RXRX

$3.11 -0.05 (-1.58%)

Closing price 08/17/2026 04:00 PM Eastern

Extended Trading

$3.06 -0.04 (-1.45%)

As of 06:53 AM Eastern

Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers. Its preclinical stage product includes RBM39 to treat HR-proficient ovarian cancer. The company has collaboration and agreement with Bayer AG; the University of Utah Research Foundation; Ohio State Innovation Foundation; Roche & Genentech; and Takeda Pharmaceutical Company Limited. Recursion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Salt Lake City, Utah.

Scholar Rock NASDAQ:SRRK

$52.05 -0.47 (-0.89%)

Closing price 08/17/2026 04:00 PM Eastern

Extended Trading

$51.80 -0.24 (-0.47%)

As of 05:54 AM Eastern

Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery, development, and delivery of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company develops Apitegromab, an inhibitor of the activation of myostatin that is in Phase 3 clinical trial for the treatment of spinal muscular atrophy; and SRK-181, which has completed Phase 1 clinical trials for the treatment of cancers that are resistant to checkpoint inhibitor therapies, such as anti-PD-1 or anti-PD-L1 antibody therapies. It is developing a pipeline of product candidates to deliver novel therapies to treat a range of serious diseases, including neuromuscular disorders, cardiometabolic disorders, cancer, fibrosis, and iron-restricted anemia. Scholar Rock Holding Corporation was founded in 2012 and is headquartered in Cambridge, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest RXRX, CGON, COGT, and SRRK Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest RXRX, CGON, COGT, and SRRK Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

RXRX, CGON, COGT, and SRRK Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

RXRX, CGON, COGT, and SRRK Company Descriptions

CG Oncology NASDAQ:CGON

Cogent Biosciences NASDAQ:COGT

Recursion Pharmaceuticals NASDAQ:RXRX

Scholar Rock NASDAQ:SRRK

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest RXRX, CGON, COGT, and SRRK Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest RXRX, CGON, COGT, and SRRK Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

RXRX, CGON, COGT, and SRRK Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

RXRX, CGON, COGT, and SRRK Company Descriptions

CG Oncology NASDAQ:CGON

Cogent Biosciences NASDAQ:COGT

Recursion Pharmaceuticals NASDAQ:RXRX

Scholar Rock NASDAQ:SRRK

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools